Humans ; Lymphoma, Non-Hodgkin ; diagnosis ; Pleural Effusion

Objective To explore the efficacy and safety of rivaroxaban in the treatment of acute intermediate-risk pulmonary thromboembolism (PTE) complicated by deep vein thrombosis (DVT) of lower limbs.Methods The clinical data on 60 patients with acute intermediate-risk PTE with DVT of lower limbs who had been treated from January 2010 to March 2015 in Hunan Provincial People's Hospital were retrospectively analysed.60 patients were divided into rivaroxaban group and control group (low molecular heparin and sequential warfarin),30 in each group.Results Echocardiogrphy results showed that the right ventricular maximum short axis diameter,right to left ventricular maximum short axis diameter ratio and pulmonary artery systolic pressure significantly decreased,but the left ventricular maximum short axis diameter significantly increased after treatment on days 10,20,and 30 in rivaroxaban group and the control group,and there was no significant difference between the two groups (P ＞ 0.05 for all comparisons).NT-proBNP level was significantly reduced after treatment on days 10,20,and 30,whilePO2 value was significantly increased after treatment on days 10 and 20,and no statistical significance between the two groups (P ＞ 0.05 for all comparisons).D-dimer was obviously higher on day 10 and lower on days 20 and 30 in rivaroxaban group than that in the control group.Conclusions Treatment withrivaroxabanfor acute intermediate-risk PTE with DVT of lower limbs is effective and safe,worthy of clinical implementation and application.

In the past ten years, the research and application of microbiome has continued to increase. The microbiome has gradually become the research focus in the fields of life science, environmental science, and medicine. Meanwhile, many countries and organizations around the world are launching their own microbiome projects and conducting a multi-faceted layout, striving to gain a strategic position in this promising field. In addition, whether it is scientific research or industrial applications, there has been a climax of research and a wave of investment and financing, accordingly, products and services related to the microbiome are constantly emerging. However, due to the rapid development of microbiome sequencing and analysis related technologies and methods, the research and application from various countries have not yet unified on the standards of technology, programs, and data. Domestic industry participants also have insufficient understanding of the microbiome. New methods, technologies, and theories have not yet been fully accepted and used. In addition, some of the existing standards and guidelines are too general with poor practicality. This not only causes obstacles in the integration of scientific research data and waste of resources, but also gives related companies unfair competition opportunity. More importantly, China still lacks national standards related to the microbiome, and the national microbiome project is still in the process of preparation. In this context, the experts and practitioners of the microbiome worked together and developed the consensus of experts. It can not only guide domestic scientific research and industrial institutions to regulate the production, learning and research of the microbiome, the application can also provide reference technical basis for the relevant national functional departments, protect the scale and standardized corporate company's interests, strengthen industry self-discipline, avoid unregulated enterprises from disrupting the market, and ultimately promote the benign development of microbiome-related industries.
China ; Consensus ; Humans ; Industry ; Microbiota